Binding Site Information of Target
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T17448 | Target Info | |||
Target Name | Histamine N-methyltransferase (HNMT) | ||||
Synonyms | Histamine-N-methyltransferase; HNMT; HMT | ||||
Target Type | Successful Target | ||||
Gene Name | HNMT | ||||
Biochemical Class | Methyltransferase | ||||
UniProt ID |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Diphenhydramine | Ligand Info | |||||
Structure Description | Histamine Methyltransferase Complexed with the Antihistamine Drug Diphenhydramine | PDB:2AOT | ||||
Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | Yes | [1] |
PDB Sequence |
> Chain A
MRSLFSDHGK 14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YEYDLLSTMD225 ISDCFIDGNE235 NGDLLWDFLT245 ETNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA> Chain B MRSLFSDHGK 14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVINN85 EVVEPSAEQI95 AKYKELVAKT105 SNLENVKFAW 115 HKETSSEYQS125 RMLEKKELQK135 WDFIHMIQML145 YYVKDIPATL155 KFFHSLLGTN 165 AKMLIIVVSG175 SSGWDKLWKK185 YGSRFPQDDL195 CQYITSDDLT205 QMLDNLGLKY 215 ECYDLLSTMD225 ISDCFIDGNE235 NGDLLWDFLT245 ETNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA
|
|||||
|
LEU8[A]
4.476
PHE9[A]
3.923
PHE19[A]
4.015
PHE22[A]
3.718
GLU28[A]
4.600
GLN143[A]
3.702
TYR146[A]
3.522
TYR147[A]
3.516
VAL173[A]
3.892
TRP179[A]
3.598
TRP183[A]
3.539
CYS196[A]
3.747
GLN197[A]
3.575
TYR198[A]
3.466
PHE243[A]
3.470
GLU246[A]
4.369
ASN283[A]
4.731
LEU8[B]
4.123
PHE9[B]
3.722
TYR15[B]
3.406
PHE19[B]
4.371
PHE22[B]
3.602
GLU28[B]
4.958
GLN143[B]
3.905
TYR146[B]
3.530
TYR147[B]
3.589
VAL173[B]
3.909
TRP179[B]
3.473
TRP183[B]
3.550
CYS196[B]
3.160
GLN197[B]
3.423
TYR198[B]
3.320
ILE199[B]
4.885
PHE243[B]
3.485
GLU246[B]
3.108
ASN283[B]
4.674
|
|||||
Ligand Name: Ergotidine | Ligand Info | |||||
Structure Description | Crystal Structure Analysis of Human Histamine Methyltransferase (Thr105 Polymorphic Variant) Complexed with AdoHcy and Histamine | PDB:1JQD | ||||
Method | X-ray diffraction | Resolution | 2.28 Å | Mutation | No | [2] |
PDB Sequence |
MRSLFHGKYV
16 ESFRRFLNHS26 TEHQCMQEFM36 DKKLPGIIGR46 IGDTKSEIKI56 LSIGGGAGEI 66 DLQILSKVQA76 QYPGVCINNE86 VVEPSAEQIA96 KYKELVAKTS106 NLENVKFAWH 116 KETSSEYQSR126 MLEKKELQKW136 DFIHMIQMLY146 YVKDIPATLK156 FFHSLLGTNA 166 KMLIIVVSGS176 SGWDKLWKKY186 GSRFPQDDLC196 QYITSDDLTQ206 MLDNLGLKYE 216 CYDLLSTMDI226 SDCFIDGNEN236 GDLLWDFLTE246 TCNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA
|
|||||
|
||||||
Ligand Name: Amodiaquine | Ligand Info | |||||
Structure Description | Histamine Methyltransferase Complexed with the Antimalarial Drug Amodiaquine | PDB:2AOU | ||||
Method | X-ray diffraction | Resolution | 2.30 Å | Mutation | Yes | [1] |
PDB Sequence |
> Chain A
MRSLFSDHGK 14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YEYDLLSTMD225 ISDCFIDGNE235 NGDLLWDFLT245 ETNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA> Chain B SMRSLFSDHG 13 KYVESFRRFL23 NHSTEHQCMQ33 EFMDKKLPGI43 IGRIGDTKSE53 IKILSIGGGA 63 GEIDLQILSK73 VQAQYPGVIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YECYDLLSTM224 DISDCFIDGN234 ENGDLLWDFL244 TETCNFNATA254 PPDLRAELGK 264 DLQEPEFSAK274 KEGKVLFNNT284 LSFIVIEA
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .CQA or .CQA2 or .CQA3 or :3CQA;style chemicals stick;color identity;select .A:6 or .A:7 or .A:8 or .A:15 or .A:16 or .A:18 or .A:19 or .A:22 or .A:28 or .A:94 or .A:97 or .A:143 or .A:146 or .A:147 or .A:173 or .A:179 or .A:180 or .A:183 or .A:184 or .A:186 or .A:187 or .A:188 or .A:190 or .A:191 or .A:192 or .A:193 or .A:196 or .A:197 or .A:198 or .A:200 or .A:203 or .A:243 or .A:245 or .A:246 or .A:247 or .A:283 or .B:5 or .B:6 or .B:7 or .B:8 or .B:15 or .B:16 or .B:19 or .B:22 or .B:28 or .B:91 or .B:94 or .B:143 or .B:146 or .B:147 or .B:173 or .B:179 or .B:183 or .B:184 or .B:187 or .B:188 or .B:190 or .B:191 or .B:193 or .B:198 or .B:243 or .B:245 or .B:246 or .B:247 or .B:283; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ARG6[A]
4.418
SER7[A]
3.704
LEU8[A]
4.579
TYR15[A]
2.892
VAL16[A]
4.035
SER18[A]
4.952
PHE19[A]
3.307
PHE22[A]
4.127
GLU28[A]
3.352
GLN94[A]
3.303
LYS97[A]
4.901
GLN143[A]
3.220
TYR146[A]
3.576
TYR147[A]
3.309
VAL173[A]
3.398
TRP179[A]
3.248
ASP180[A]
3.388
TRP183[A]
3.303
LYS184[A]
3.538
TYR186[A]
4.585
GLY187[A]
3.321
SER188[A]
4.382
PHE190[A]
3.395
PRO191[A]
3.090
GLN192[A]
4.710
ASP193[A]
3.714
CYS196[A]
3.318
GLN197[A]
4.948
TYR198[A]
3.295
THR200[A]
4.678
ASP203[A]
4.807
PHE243[A]
3.637
THR245[A]
3.184
GLU246[A]
3.081
THR247[A]
3.657
ASN283[A]
4.670
MET5[B]
4.115
ARG6[B]
3.419
SER7[B]
3.248
LEU8[B]
4.887
TYR15[B]
2.574
VAL16[B]
4.148
PHE19[B]
3.233
PHE22[B]
3.884
GLU28[B]
3.410
SER91[B]
3.692
GLN94[B]
3.386
GLN143[B]
3.317
TYR146[B]
3.548
TYR147[B]
3.735
VAL173[B]
3.572
TRP179[B]
3.176
TRP183[B]
3.435
LYS184[B]
4.657
GLY187[B]
3.420
SER188[B]
4.485
PHE190[B]
3.368
PRO191[B]
3.100
ASP193[B]
3.561
TYR198[B]
3.201
PHE243[B]
3.641
THR245[B]
2.837
GLU246[B]
3.718
THR247[B]
3.563
ASN283[B]
4.731
|
|||||
Ligand Name: Tacrine | Ligand Info | |||||
Structure Description | Histamine Methyltransferase (Natural Variant I105) Complexed with the Acetylcholinesterase Inhibitor and Altzheimer's Disease Drug Tacrine | PDB:2AOW | ||||
Method | X-ray diffraction | Resolution | 2.97 Å | Mutation | Yes | [1] |
PDB Sequence |
MRSLFSDHGK
14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 ISNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YECYDLLSTM224 DISDCFIDGN234 ENGDLLWDFL244 TETCNFNATA254 PPDLRAELGK 264 DLQEPEFSAK274 KEGKVLFNNT284 LSFIVIEA
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .THA or .THA2 or .THA3 or :3THA;style chemicals stick;color identity;select .A:15 or .A:19 or .A:22 or .A:28 or .A:143 or .A:146 or .A:147 or .A:173 or .A:179 or .A:183 or .A:243 or .A:246 or .A:283; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Ligand Name: Metoprine | Ligand Info | |||||
Structure Description | Histamine Methyltransferase Complexed with the Antifolate Drug Metoprine | PDB:2AOV | ||||
Method | X-ray diffraction | Resolution | 2.48 Å | Mutation | No | [1] |
PDB Sequence |
MRSLFSDHGK
14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YECYDLLSTM224 DISDCFIDGN234 ENGDLLWDFL244 TETCNFNATA254 PPDLRAELGK 264 DLQEPEFSAK274 KEGKVLFNNT284 LSFIVIEA
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .C2M or .C2M2 or .C2M3 or :3C2M;style chemicals stick;color identity;select .A:15 or .A:19 or .A:22 or .A:28 or .A:143 or .A:146 or .A:147 or .A:173 or .A:179 or .A:183 or .A:196 or .A:197 or .A:198 or .A:199 or .A:243 or .A:244 or .A:246 or .A:283; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
Ligand Name: Cysteine Sulfenic Acid | Ligand Info | |||||
Structure Description | Histamine Methyltransferase Complexed with the Antihistamine Drug Diphenhydramine | PDB:2AOT | ||||
Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | Yes | [1] |
PDB Sequence |
> Chain A
MRSLFSDHGK 14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YEYDLLSTMD225 ISDCFIDGNE235 NGDLLWDFLT245 ETNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA> Chain B MRSLFSDHGK 14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVINN85 EVVEPSAEQI95 AKYKELVAKT105 SNLENVKFAW 115 HKETSSEYQS125 RMLEKKELQK135 WDFIHMIQML145 YYVKDIPATL155 KFFHSLLGTN 165 AKMLIIVVSG175 SSGWDKLWKK185 YGSRFPQDDL195 CQYITSDDLT205 QMLDNLGLKY 215 ECYDLLSTMD225 ISDCFIDGNE235 NGDLLWDFLT245 ETNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .CSO or .CSO2 or .CSO3 or :3CSO;style chemicals stick;color identity;select .A:6 or .A:7 or .A:8 or .A:10 or .A:11 or .A:14 or .A:201 or .A:205 or .A:215 or .A:216 or .A:218 or .A:219 or .A:242 or .A:246 or .A:247 or .A:249 or .A:250 or .A:253 or .A:286 or .A:287 or .A:288 or .B:113 or .B:6 or .B:7 or .B:8 or .B:10 or .B:11 or .B:14 or .B:52 or .B:53 or .B:54 or .B:80 or .B:81 or .B:83 or .B:84 or .B:109 or .B:110 or .B:242 or .B:246 or .B:247 or .B:249 or .B:250 or .B:253; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ARG6[A]
2.863
SER7[A]
3.733
LEU8[A]
3.679
SER10[A]
4.108
ASP11[A]
3.139
LYS14[A]
3.316
SER201[A]
3.100
THR205[A]
3.493
TYR215[A]
4.353
GLU216[A]
1.330
TYR218[A]
1.328
ASP219[A]
3.891
ASP242[A]
3.485
GLU246[A]
4.520
THR247[A]
1.328
ASN249[A]
1.331
PHE250[A]
3.548
THR253[A]
4.188
SER286[A]
3.793
PHE287[A]
3.373
ILE288[A]
3.617
PHE113[B]
4.817
ARG6[B]
2.980
SER7[B]
3.549
LEU8[B]
3.664
SER10[B]
4.376
ASP11[B]
2.945
LYS14[B]
4.586
SER52[B]
4.134
GLU53[B]
3.449
ILE54[B]
2.900
GLY80[B]
3.635
VAL81[B]
1.331
ILE83[B]
1.321
ASN84[B]
4.305
GLU109[B]
4.976
ASN110[B]
3.543
ASP242[B]
4.101
GLU246[B]
4.489
THR247[B]
1.330
ASN249[B]
1.327
PHE250[B]
3.252
THR253[B]
3.871
|
|||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Ligand Name: Mepacrine | Ligand Info | |||||
Structure Description | Crystal Structure Analysis of Human Histamine Methyltransferase (Ile105 Polymorphic Variant) Complexed with AdoHcy and Antimalarial Drug Quinacrine | PDB:1JQE | ||||
Method | X-ray diffraction | Resolution | 1.91 Å | Mutation | Yes | [2] |
PDB Sequence |
GKYVESFRRF
22 LNHSTEHQCM32 QEFMDKKLPG42 IIGRIGDTKS52 EIKILSIGGG62 AGEIDLQILS 72 KVQAQYPGVC82 INNEVVEPSA92 EQIAKYKELV102 AKISNLENVK112 FAWHKETSSE 122 YQSRMLEKKE132 LQKWDFIHMI142 QMLYYVKDIP152 ATLKFFHSLL162 GTNAKMLIIV 172 VSGSSGWDKL182 WKKYGSRFPQ192 DDLCQYITSD202 DLTQMLDNLG212 LKYECYDLLS 222 TMDISDCFID232 GNENGDLLWD242 FLTETCNFNA252 TAPPDLRAEL262 GKDLQEPEFS 272 AKKEGKVLFN282 NTLSFIVIEA292
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .QUN or .QUN2 or .QUN3 or :3QUN;style chemicals stick;color identity;select .A:15 or .A:16 or .A:18 or .A:19 or .A:94 or .A:146 or .A:147 or .A:173 or .A:179 or .A:183 or .A:193 or .A:195 or .A:196 or .A:197 or .A:198 or .A:243 or .A:246; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
Ligand Name: D-cysteine | Ligand Info | |||||
Structure Description | Histamine Methyltransferase Complexed with the Antimalarial Drug Amodiaquine | PDB:2AOU | ||||
Method | X-ray diffraction | Resolution | 2.30 Å | Mutation | Yes | [1] |
PDB Sequence |
MRSLFSDHGK
14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YEYDLLSTMD225 ISDCFIDGNE235 NGDLLWDFLT245 ETNFNATAPP256 DLRAELGKDL 266 QEPEFSAKKE276 GKVLFNNTLS286 FIVIEA
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .DCY or .DCY2 or .DCY3 or :3DCY;style chemicals stick;color identity;select .A:5 or .A:6 or .A:7 or .A:8 or .A:10 or .A:11 or .A:14 or .A:242 or .A:246 or .A:247 or .A:249 or .A:250 or .A:253; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
Ligand Name: 4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE | Ligand Info | |||||
Structure Description | Histamine Methyltransferase Complexed with the Antifolate Drug Metoprine | PDB:2AOV | ||||
Method | X-ray diffraction | Resolution | 2.48 Å | Mutation | No | [1] |
PDB Sequence |
MRSLFSDHGK
14 YVESFRRFLN24 HSTEHQCMQE34 FMDKKLPGII44 GRIGDTKSEI54 KILSIGGGAG 64 EIDLQILSKV74 QAQYPGVCIN84 NEVVEPSAEQ94 IAKYKELVAK104 TSNLENVKFA 114 WHKETSSEYQ124 SRMLEKKELQ134 KWDFIHMIQM144 LYYVKDIPAT154 LKFFHSLLGT 164 NAKMLIIVVS174 GSSGWDKLWK184 KYGSRFPQDD194 LCQYITSDDL204 TQMLDNLGLK 214 YECYDLLSTM224 DISDCFIDGN234 ENGDLLWDFL244 TETCNFNATA254 PPDLRAELGK 264 DLQEPEFSAK274 KEGKVLFNNT284 LSFIVIEA
|
|||||
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .4DI or .4DI2 or .4DI3 or :34DI;style chemicals stick;color identity;select .A:15 or .A:19 or .A:59 or .A:60 or .A:88 or .A:89 or .A:90 or .A:118 or .A:119 or .A:120 or .A:144 or .A:147 or .A:148; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Structural basis for inhibition of histamine N-methyltransferase by diverse drugs. J Mol Biol. 2005 Oct 21;353(2):334-344. | ||||
REF 2 | Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure. 2001 Sep;9(9):837-49. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.